Zydus approves Rs 1,100 cr share buyback

Zydus Lifesciences Limited has approved a proposal to buy back up to 95,65,217 fully paid-up equity shares at a price of INR 1,150 per share. The buyback size aggregates to INR 1,100 crore, representing 0.95% of the total number of equity shares in the paid-up equity share capital of the Company. The Board approved the proposal at its meeting held on May 19, 2026.

Buyback Details

The buyback will be conducted through the tender offer route and is open to all equity shareholders, including promoters, holding shares as of the record date. The aggregate amount does not include transaction costs such as brokerage, taxes, and other incidental expenses. The Board has also formed a Buyback Committee to oversee the process.

Parameter Details Number of Shares 95,65,217 Buyback Price INR 1,150 per share Buyback Size INR 1,100 crore Percentage of Paid-up Capital 0.95% Record Date May 29, 2026

Record Date and Shareholding Pattern

Company has fixed May 29, 2026, as the record date to determine the eligibility of shareholders for the buyback. The pre-buyback shareholding pattern as of May 15, 2026, indicates that the promoter and promoter group held 74.9950% of the total equity shares. The post-buyback pattern will be ascertained after the record date.

Shareholder Category % of Shareholding Promoter and promoter group 74.9950 Foreign portfolio investor 6.8586 Insurance companies 6.1195 Mutual funds 4.8978 Individuals (upto INR 2 lacs) 4.8512

The Board may increase the buyback price or decrease the number of shares until one working day prior to the record date, provided the buyback size remains unchanged. The public announcement and letter of offer will be released in due course.

Zydus Lifesciences Limited reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, on May 19, 2026. The Board recommended a final dividend of 100%, or Re. 1/- per equity share, subject to shareholder approval at the Annual General Meeting scheduled for August 11, 2026. Additionally, the Board approved a buyback of equity shares for an aggregate amount of up to INR 11,000 million at a price of INR 1,150 per share.

Consolidated Financial Performance

On a consolidated basis, the company reported total revenue from operations of INR 271,484 million for FY26, an increase of 16.8% from INR 232,415 million in FY25. Consolidated net profit for the year stood at INR 50,400 million, while adjusted net profit rose 15% to INR 54,564 million. For the quarter ended March 31, 2026, revenue from operations was INR 75,870 million, and net profit was INR 12,725 million. Adjusted net profit for Q4 FY26 was INR 15,929 million.

The following table summarises the consolidated financial results:

Metric (INR Mn) Q4 FY26 Q4 FY25 % Gr. YoY FY26 FY25 % Gr. YoY Revenue from Operations 75,870 65,279 16.2% 271,484 232,415 16.8% EBITDA 25,544 21,255 20.2% 84,751 70,585 20.1% Net Profit 12,725 11,709 50,400 45,255 Adjusted Net Profit 15,929 13,905 14.6% 54,564 47,451 15.0%

Consolidated exceptional items for FY26 totalled INR 5,166 million, including a one-time settlement payment of INR 3,975 million related to a Settlement and License Agreement with Astellas Pharma Inc. concerning Myrtebriq® (Mirabegron).

Standalone Financial Performance

On a standalone basis, Zydus Lifesciences reported total revenue from operations of INR 114,840 million for FY26, compared to INR 151,163 million in the previous year. Net profit for the year stood at INR 35,598 million, against INR 57,749 million in the prior year. The quarter ended March 31, 2026 recorded standalone revenue from operations of INR 37,409 million and net profit of INR 17,220 million.

Metric (INR Mn) Q4 FY26 Q3 FY26 Q4 FY25 FY26 FY25 Revenue from Operations 37,409 22,836 58,196 114,840 151,163 Net Profit 17,220 2,965 28,137 35,598 57,749

Segment-Wise Performance

The consolidated segment results for FY26 reflect growth across the Pharmaceuticals and Consumer Products segments. The Pharmaceuticals business reported revenue of INR 220,240 million, while Consumer Wellness revenue stood at INR 39,134 million.

Segment FY26 Revenue (INR Mn) FY25 Revenue (INR Mn) % Gr. YoY Pharmaceuticals 220,240 198,904 10.7% Consumer Wellness 39,134 26,810 46.0% MedTech 7,823 24 Total 267,197 225,738 18.4%

Key Developments

During the year, Zydus Lifesciences completed the acquisition of Amplitude Surgical SA, France, and Comfort Click Limited. Zylidac Bio LLC acquired two U.S.-based biologics manufacturing facilities of Agenus. On May 13, 2026, Zydus Worldwide DMCC signed a definitive agreement to acquire Assertio Holdings, Inc. for approximately USD 166.4 million. The company's net debt to equity ratio as of March 31, 2026, was 0.16x.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.